Abbott's Advisor HD Grid Mapping Catheter Gains Approval in China, Setting a New Standard for Precision in Atrial Fibrillation Treatment

On August 21, Abbott, a global leader in healthcare, announced that its next-generation single-use mesh magnetic-electric localization mapping catheter (hereinafter referred to as the Advisor HD Grid Mapping Catheter), representing cutting-edge technology in the field of electrophysiology, has been approved in China. This approval elevates the precision of both substrate mapping and activation mapping to new heights. The approval of the Advisor HD Grid Mapping Catheter marks an additional, more precise option for physicians and patients in China in the treatment of arrhythmias such as atrial fibrillation.

Atrial Fibrillation (AFib) is a common arrhythmia encountered in daily life. Patients often face risks such as chest tightness, palpitations, heart failure, and stroke, which not only impair quality of life but can also be life-threatening in severe cases. In China, approximately 10 million people are suffering from this condition. How to cure atrial fibrillation and mitigate the harm caused by this disease has remained a significant focus of attention.

As the world’s first mesh-type high-density mapping catheter, the Advisor HD Grid Mapping Catheter features a soft tip that deforms to varying degrees in response to changes in contact force, thereby visualizing pressure and overcoming pseudo-low-voltage artifacts caused by factors such as inadequate tissue contact. It enables rapid and safe high-density mapping throughout all cardiac chambers, while also recording electrograms and delivering electrical stimulation to acquire high-quality low-voltage signals from the atria and ventricles. This helps physicians thoroughly understand the substrate of local myocardial pathology and formulate optimal ablation strategies. Furthermore, the Advisor HD Grid Mapping Catheter overcomes the limitations imposed by the direction of electrical conduction, avoiding information loss associated with traditional procedures or other products on the market due to variations in conduction direction.

Catheter ablation is currently one of the effective curative treatments for atrial fibrillation. Compared with pharmacological therapy, catheter ablation can effectively eliminate the substrates that maintain atrial fibrillation, reduce the frequency of atrial fibrillation episodes, and improve patients’ quality of life. At the 38th Annual Scientific Sessions of the Heart Rhythm Society (HRS 2017), varying proportions of committee members recommended substrate mapping-guided ablation strategies, regardless of whether it was a first-time or repeat ablation, or for paroxysmal or persistent atrial fibrillation.

Meanwhile, relevant studies have shown that as atrial fibrillation (AF) progresses, the degree of atrial fibrosis increases. Compared with patients with paroxysmal AF or the normal population, patients with persistent AF exhibit a significantly greater distribution of low-voltage and scar areas within the left atrium. It can thus be inferred that the persistence of AF may be associated with this phenomenon. Therefore, accurate assessment of low-voltage areas is conducive to formulating individualized ablation strategies and improving the success rate of AF ablation. However, due to factors such as the direction of electrical conduction and inadequate catheter contact in previous mapping techniques, artifacts mimicking low-voltage areas often occur, thereby affecting clinicians’ treatment decisions.

In January 2019, during two atrial fibrillation radiofrequency ablation procedures at the International Heart Medical Center of Hainan Boao Super Hospital, the Advisor HD Grid mapping catheter, in conjunction with Abbott’s EnSite Precision 3D mapping system and the next-generation TactiCath SE ablation catheter, were integrated from three dimensions to work synergistically, marking their first clinical application in China. With the official market launch of this catheter in China, it will benefit a broader population of Chinese patients with arrhythmias, helping to alleviate disease burden and improve quality of life.